Skip to main content
SpringerLink
Log in

Rituximab

Halbe Dosis mit voller Stärke?

Rituximab

Half dose with full strength?

  • Klinische Studien kurzgefasst
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Bredemeier M, Oliveira FK de, Rocha CM (2014) Low- versus high-dose rituximab for rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 66(2):228–235

    Article  Google Scholar 

  2. Vital EM, Dass S, Buch MH et al (2014) An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial. Ann Rheum Dis. doi:10.1136/annrheumdis-2013-204544. (Online veröffentlicht vor Drucklegung)

Download references

Interessenkonflikt

E. Feist ist als Referent für die Firma Roche Pharma tätig gewesen und erhielt Beraterhonorare von der Firma Roche Pharma.

Author information

Authors and Affiliations

  1. Med. Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie, Charite Universitätsmedizin Berlin, Chariteplatz 01, 10098, Berlin, Deutschland

    E. Feist

Authors
  1. E. Feist
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Feist.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Feist, E. Rituximab. Z. Rheumatol. 73, 856–857 (2014). https://doi.org/10.1007/s00393-014-1453-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-014-1453-5

Search

Navigation